Role of NKG2D-expressing NK cells and sMICA in immune surveillance of advanced lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 1, 2009, Pages 59-63

  Liang, Jing ^a   Han, Lucai ^b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Shanxi Provincial Tumor Hospital   (China)

Author keywords

Immunologic monitoring; Lung neoplasms; MHC class I related chain A; Natural killer cell activating receptors

Indexed keywords

HLA A ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D;

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOSURVEILLANCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE SUBPOPULATION;

EID: 60149096005     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.01.010     Document Type: Article

References (10)

1. Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG-2D immunoreceptor in immune cell activation and natural killing. Immunity, 2002, 17(1): 19-29.
2. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I -related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 2002, 62(21): 6178-6186.
3. Groh V, Wu J, Yee C, et al. Tumor-devived soluble MIC Ligands impair expression of NKG2D and T-cell activation. Nature, 2002, 419(6908): 734-738.
4. Finn OJ, Lotze MT. A decade in the life of tumor immunology. Clin Cancer Res, 2001, 7(3): 759-760.
5. Leibson PJ. Signal transduction during nature killer cell activation:inside the mind of a killer. Immunity, 1997, 6(6): 655-661.
6. Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor:expression by tumor cells and activation of NK cells and macrophages. Nat Immunnol, 2000, 1(2): 119-126.
7. Eriese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res, 2004, 64(20): 7596-7603.
8. Le Maux Chansac B, Moretta A, Vergnon I, et al. NK Cells infiltrating a MHC Class I-Deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol, 2005, 175(9): 5790-5798.
9. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICA in malignant diseases. Int J Cancer, 2006, 118(3): 684-687.
10. Rebmann V, Schutt P, Brandhorst D, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol, 2007, 123(1): 114-120.